IP Library Granted Patent US 10,646,581
Granted Patent B2
US 10,646,581 · App. 15/990,136 · Granted May 12, 2020

PSMA binding ligand-linker conjugates and methods for using

Inventors: Philip S. Low (West Lafayette, IN); Sumith A. Kularatne (West Lafayette, IN)
Assignee: Purdue Research Foundation
A61K47/64A61K31/426A61K31/475A61K31/4745A61K47/54A61K47/542A61K47/547A61K47/548A61K49/0041A61K49/0043A61K49/0052A61K49/0056A61K51/04A61K51/0402A61K51/0489A61K51/088C07C323/52C07D207/416C07K5/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,646,581
App. No.
15/990,136
Granted
May 12, 2020
Kind
B2
Abstract

Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

Claims (20)

1. A compound of the formula:

B-L-D   

or a salt thereof, wherein

B comprises a urea of two amino acids, wherein each amino acid is independently an aminoalkylcarboxylate substituted with alkyl, hydroxyalkyl, sulfhydrylalkyl, aminoalkyl, or carboxyalkyl;

L comprises at least one hydrophobic side chain group that is arylalkyl comprising a naphthyl group and is 14 to 24 atoms in length; and

D is a radioisotope.

2. The compound of claim 1 or a salt thereof, wherein B is of the formula

wherein R 1 is hydrogen and R 2 is a substituted carboxylic acid, wherein the substituted carboxylic acid is covalently hound to the linker.

3. The compound of claim 1 or a salt thereof, wherein L comprises one or more Arg, Lys, Asp, Glu, and Gln.

4. The compound of claim 3 or a salt thereof, wherein L comprises Glu.

5. The compound of claim 2 or a salt thereof, wherein L comprises one or more Arg, Lys, Asp, Glu, and Gln.

6. The compound of claim 5 or a salt thereof, wherein L comprises Glu.

7. A pharmaceutical composition comprising a compound of claim 1 or a salt thereof and at least one pharmaceutically acceptable carrier, excipient, or a combination thereof.

8. The compound of claim 1 or a salt thereof, wherein the linker comprises an alkane, alkene, alkyne, cycloalkane, arylene, or imide.

9. The compound of claim 1 or a salt thereof, wherein the linker comprises an arylene.

10. The compound of claim 1 or a salt thereof, wherein the linker is covalently bound to B via an amide bond.

11. The compound of claim 1 or a salt thereof, wherein the linker is covalently bound to D via an amide bond.

12. A reconstitutable lyophilizate comprising a compound of claim 1 or a salt thereof.

13. The reconstitutable lyophilizate of claim 12 wherein the lyophilizate comprises a dose of the compound of claim 1 or a salt thereof.

14. A kit comprising the reconstitutable lyophilizate of claim 12 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: LOW, PHILIP STEWART; KULARATNE, SUMITH A.
To: PURDUE RESEARCH FOUNDATION
Reel/Frame 051224/0323 →
Continuity (6)
Continuation 15606913 · May 26, 2017
Continuation 14794482 · Jul 8, 2015
Continuation 12673931
Provisional Application 61074358 · Jun 20, 2008
Provisional Application 60956489 · Aug 17, 2007
Related Publication 20180289828A1 · Oct 11, 2018
Cited By (7)
US 12,208,102 US 12,297,218 US 12,324,846 US 12,473,265 US 12,496,292 US 12,551,527 US 12,655,115